Christopher Rogers, DO
Cardiovascular Disease · Kalamazoo, MINPI 1013937036
Payments from drug & device makers
Across 446 payments — averaging $167.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$43K
- Medtronic$19K
- Boston Scientific$6K
- Abbott$2K
- Edwards Lifesciences$1K
- Shockwave Medical, Inc$630
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$5,00015%
- Travel & lodging$13,63242%
- Food & beverage$13,76542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 34 | $42,789 |
| Medtronic(2 entities) | 144 | $18,521 |
| Boston Scientific | 45 | $6,324 |
| Abbott | 48 | $2,485 |
| Edwards Lifesciences | 25 | $1,297 |
| Shockwave Medical, Inc | 25 | $630 |
| Cardiva Medical, Inc. | 10 | $413 |
| Pfizer | 21 | $355 |
| Cardiovascular Systems Inc. | 11 | $317 |
| Abiomed | 6 | $206 |
| E.r. Squibb & Sons, L.L.C. | 11 | $172 |
| Johnson & Johnson | 9 | $148 |
| Actelion Pharmaceuticals US, Inc. | 6 | $131 |
| Daiichi Sankyo Inc. | 5 | $96 |
| AstraZeneca | 7 | $89 |
| Amgen | 6 | $86 |
| Philips North America LLC | 3 | $73 |
| Teleflex LLC | 3 | $71 |
| Amarin Pharma, Inc. | 4 | $63 |
| Lantheus Medical Imaging, Inc. | 1 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $37 |
| Chiesi USA, Inc. | 1 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Boehringer Ingelheim | 2 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Merck | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Cordis US CORP. | 1 | $16 |
| Livanova USA, Inc. | 1 | $14 |
| Bayer | 1 | $12 |
| Cardinal Health 200 LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$14,863
- WATCHMAN Access System$5,299
- Cardiac Mapping System$740
- CoreValve Evolut$491
- Edwards SAPIEN 3 Transcatheter Heart Valve$411
- Mitra Clip system$253
- MitraClip$178
- Quadra Assura CRT Defibrillator$173
- Xience Sierra Coronary Stent$150
- SAPIEN 3 Ultra RESILIA$133
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$124
- Diamondback Coronary$115
- Micra$109
How this compares
$74,698 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 424 | $475,018 |
| EntrestoSacubitril/Valsartan | 189 | $226,625 |
| XareltoRivaroxaban | 104 | $114,992 |
| BrilintaTicagrelor | 79 | $66,322 |
| Repatha SureclickEvolocumab | 64 | $51,414 |
| JardianceEmpagliflozin | 33 | $39,257 |
| FarxigaDapagliflozin Propanediol | 30 | $31,118 |
| Metoprolol Succinate | 746 | $14,209 |
| ClopidogrelClopidogrel Bisulfate | 478 | $8,038 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 307 | $6,740 |
| Repatha SyringeEvolocumab | 11 | $5,854 |
| Ranolazine ErRanolazine | 54 | $5,846 |
| Losartan Potassium | 199 | $3,012 |
| Ezetimibe | 90 | $2,870 |
| Rosuvastatin Calcium | 180 | $2,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $355 | $475,018424 claims |
| NovartisEntresto | $42,789 | $226,625189 claims |
| Johnson & JohnsonXarelto | $148 | $114,992104 claims |
| AstraZenecaBrilinta, Farxiga | $89 | $97,440109 claims |
| Boehringer IngelheimJardiance | $31 | $39,25733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Kalamazoo
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
- Waleed DoghmiMidland$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.